ReviewArchives of microbiology2025
Microbial proteases as emerging anti-inflammatory therapeutics: a comprehensive review.
Review in Archives of microbiology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Inflammation is the body's natural defence response to pathogens or tissue injury. This review explores the therapeutic potential of microbial proteases in managing inflammation, focusing on their molecular mechanisms, production strategies, and emerging role as alternatives to conventional anti-inflammatory drugs. While standard treatments such as Non-Steroidal Anti-Inflammatory Drugs (NSAIDs) and glucocorticoids act by inhibiting cyclooxygenase enzymes and prostaglandin synthesis, their prolonged use is often associated with adverse effects, including gastrointestinal ulcers, renal toxicity, and cardiovascular complications. Microbial proteases, by contrast, offer advantages such as catalytic specificity, biochemical diversity, and ease of large-scale production through fermentation and genetic modification. In addition to examining market trends of the currently available enzyme-based therapies, this review highlights several key considerations limiting their clinical adoption-namely, immune system sensitivity, poor stability under physiological conditions, limited comparative performance data against other enzyme sources, and challenges in regulatory approval and targeted delivery. It also uniquely highlights underexplored bacterial genera and production challenges, offering a translational outlook that bridges laboratory findings with real-world therapeutic applications. Advances in strain engineering, encapsulation techniques, and synthetic biology approaches hold promise for enhancing the safety, effectiveness, and precision of microbial protease-based therapeutics in inflammation control.
Indexed as
Identifiers
40828296What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.